- Home
- PBYI vs VTYX Comparison
PBYI vs VTYX Comparison
Compare PBYI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- VTYX
- Stock Information
- Founded
- PBYI 2010
- VTYX 2018
- Country
- PBYI United States
- VTYX United States
- Employees
- PBYI N/A
- VTYX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- PBYI Health Care
- VTYX Health Care
- Exchange
- PBYI Nasdaq
- VTYX Nasdaq
- Market Cap
- PBYI 138.4M
- VTYX 154.9M
- IPO Year
- PBYI N/A
- VTYX 2021
- Fundamental
- Price
- PBYI $3.07
- VTYX $1.17
- Analyst Decision
- PBYI Strong Buy
- VTYX Buy
- Analyst Count
- PBYI 1
- VTYX 4
- Target Price
- PBYI $7.00
- VTYX $11.33
- AVG Volume (30 Days)
- PBYI 275.3K
- VTYX 965.2K
- Earning Date
- PBYI 05-08-2025
- VTYX 05-16-2025
- Dividend Yield
- PBYI N/A
- VTYX N/A
- EPS Growth
- PBYI 37.78
- VTYX N/A
- EPS
- PBYI 0.62
- VTYX N/A
- Revenue
- PBYI $230,468,000.00
- VTYX N/A
- Revenue This Year
- PBYI N/A
- VTYX N/A
- Revenue Next Year
- PBYI N/A
- VTYX N/A
- P/E Ratio
- PBYI $4.92
- VTYX N/A
- Revenue Growth
- PBYI N/A
- VTYX N/A
- 52 Week Low
- PBYI $2.23
- VTYX $0.78
- 52 Week High
- PBYI $5.20
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- PBYI 51.76
- VTYX 46.01
- Support Level
- PBYI $2.88
- VTYX $1.05
- Resistance Level
- PBYI $3.14
- VTYX $1.48
- Average True Range (ATR)
- PBYI 0.14
- VTYX 0.11
- MACD
- PBYI 0.01
- VTYX 0.01
- Stochastic Oscillator
- PBYI 64.00
- VTYX 27.91
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.